Premium
Hemoglobin‐based Red Blood Cell Substitutes
Author(s) -
Chang Thomas Ming Swi
Publication year - 2004
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/j.1525-1594.2004.07394.x
Subject(s) - hemoglobin , nitric oxide , red blood cell , clinical trial , medicine , pharmacology , chemistry , biochemistry , immunology
Polyhemoglobin is already well into the final stages of clinical trials in humans with one approved for routine clinical use in South Africa. Conjugated hemoglobin is also in ongoing clinical trials. Meanwhile, recombinant Hb has been modified to modulate the effects of nitric oxide. Other systems contain antioxidant enzymes for those clinical applications that may have potential problems related to ischemia‐reperfusion injuries. Other developments are based on hemoglobin‐lipid vesicles and also the use of nanotechnology and biodegradable copolymers to prepare nanodimension artificial red blood cells containing hemoglobin and complex enzyme systems.